Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to 353.42%.

  • Cue Biopharma's EBIT Margin fell 891800.0% to 353.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 537.49%, marking a year-over-year decrease of 580800.0%. This contributed to the annual value of 446.86% for FY2024, which is 5030300.0% up from last year.
  • According to the latest figures from Q3 2025, Cue Biopharma's EBIT Margin is 353.42%, which was down 891800.0% from 292.32% recorded in Q2 2025.
  • Cue Biopharma's 5-year EBIT Margin high stood at 95.62% for Q4 2021, and its period low was 50346.15% during Q2 2022.
  • Its 5-year average for EBIT Margin is 4982.42%, with a median of 737.8% in 2024.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -499699900bps in 2022, then skyrocketed by 493680800bps in 2023.
  • Quarter analysis of 5 years shows Cue Biopharma's EBIT Margin stood at 95.62% in 2021, then tumbled by -10196bps to 9845.03% in 2022, then soared by 92bps to 759.58% in 2023, then rose by 20bps to 611.23% in 2024, then skyrocketed by 42bps to 353.42% in 2025.
  • Its EBIT Margin was 353.42% in Q3 2025, compared to 292.32% in Q2 2025 and 2921.38% in Q1 2025.